Table 4.
The comparison with metachronous GA and without metachronous GA
| n | Metachronous GA+ | p value | Odds ratio | 95% CI | |
|---|---|---|---|---|---|
| Sex |
|
|
|
|
|
| M |
71 |
6 (8%) |
0.4 |
1.47 |
0.40–5.48 |
| F |
68 |
4 (6%) |
|||
| Age |
|
|
|
|
|
| 60≦ |
64 |
1 (2%) |
0.02※ |
8.59 |
1.06–69.78 |
| 60> |
75 |
9 (12%) |
|||
| Histology of Lymphoma |
|
|
|
|
|
| DLBCL |
83 |
10 (12%) |
0.007※ |
- |
- |
| MALT |
51 |
0 |
|||
| HP Infection |
|
|
|
|
|
| HP positive |
22 |
5 (23%) |
0.007※ |
- |
- |
| HP negative |
34 |
0 |
|||
| Chemotherapy |
|
|
|
|
|
| Yes |
88 |
10 (11%) |
0.009※ |
- |
- |
| No |
51 |
0 |
|||
| Rituximab |
|
|
|
|
|
| Yes |
40 |
3 (8%) |
0.59 |
1.07 |
0.26–4.34 |
| No |
99 |
7 (7%) |
|||
| Stage |
|
|
|
|
|
| Stage I |
93 |
3 (3%) |
0.02※ |
5.38 |
1.32–21.92 |
| Stage II-IV |
46 |
7 (15%) |
|||
| Chronic Gastritis |
|
|
|
|
|
| Yes |
65 |
9 (14%) |
0.26 |
3.05 |
0.36–25.71 |
| No |
20 |
1 (5%) |
|||
| Intestinal Metaplasia |
|
|
|
|
|
| Yes |
29 |
6 (21%) |
0.07 |
3.39 |
0.87–13.17 |
| No | 56 | 4 (7%) |
GA: gastric adenocarcinoma.
CI: confidence interval.
※ p<0.05.